Ryan M Mercer

US Patent:

8299025, Oct 30, 2012

Filed:

Apr 22, 2008

Appl. No.:

12/148896

Inventors:

Thomas R. Alessi - Hayward CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US

Assignee:

Intarcia Therapeutics, Inc. - Hayward CA

International Classification:

A61K 38/26
A61P 3/10

US Classification:

514 72, 514 68, 514 69

Abstract:

A suspension formulation of an insulinotropic peptide (e. g. , glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.

US Patent:

8343140, Jan 1, 2013

Filed:

Feb 12, 2009

Appl. No.:

12/378341

Inventors:

Thomas R. Alessi - Hayward CA, US
Karling Alice Leung - Oakland CA, US
Ryan D. Mercer - Dublin CA, US
Cristina G. Negulescu - Santa Clara CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US

Assignee:

Intarcia Therapeutics, Inc. - Hayward CA

International Classification:

A61K 9/22

US Classification:

6048921

Abstract:

The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.

US Patent:

20100092566, Apr 15, 2010

Filed:

Oct 14, 2009

Appl. No.:

12/587946

Inventors:

Thomas R. Alessi - Hayward CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US

International Classification:

A61K 9/14
A61K 47/26
A61K 31/197
A61K 31/405
A61K 38/02
A61K 38/21
A61K 38/26
A61K 39/395

US Classification:

424489, 514777, 514562, 514419, 514 2, 424 854, 514 12, 4241301, 4241331, 4241351, 4241411

Abstract:

Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability.

US Patent:

20120178687, Jul 12, 2012

Filed:

Nov 15, 2010

Appl. No.:

12/927432

Inventors:

Thomas R. Alessi - Hayward CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US

International Classification:

A61K 38/26
A61M 37/00
B23P 17/04
A61P 3/10

US Classification:

514 117, 6048921, 2989009

Abstract:

A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.

US Patent:

20120289944, Nov 15, 2012

Filed:

Jul 7, 2012

Appl. No.:

13/543821

Inventors:

Thomas R. Alessi - Hayward CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US

Assignee:

INTARCIA THERAPEUTICS, INC. - Hayward CA

International Classification:

A61M 37/00

US Classification:

6048921

Abstract:

Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability.

US Patent:

20130090287, Apr 11, 2013

Filed:

Nov 29, 2012

Appl. No.:

13/689410

Inventors:

Thomas R. Alessi - Hayward CA, US
Karling Alice Leung - Oakland CA, US
Ryan D. Mercer - Dublin CA, US
Cristina G. Negulescu - Santa Clara CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US

Assignee:

INTARCIA THERAPEUTICS, INC. - Hayward CA

International Classification:

A61K 47/32

US Classification:

514 53, 514 117, 514 72

Abstract:

The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.

US Patent:

20220375348, Nov 24, 2022

Filed:

May 24, 2021

Appl. No.:

17/328333

Inventors:

- Plano TX, US
Ryan Mercer - Colton CA, US

Assignee:

Toyota Motor Engineering & Manufacturing North America, Inc. - Plano TX

International Classification:

G08G 1/16
G07C 5/00
G06N 20/00
G08G 1/00
G08G 1/01

Abstract:

A method includes, at a first level manager, receiving vehicle data from a plurality of vehicles, aggregating the vehicle data, determining a first variable associated with the plurality of vehicles based on the aggregated vehicle data, and transmitting the aggregated vehicle data to a second level manager. The second level manager is in a higher hierarchical level than the first level manager. The method further includes, at a second level manager, determining a second variable based on the received aggregated vehicle data, determining whether the first and second variable conform to a predetermined dependency among the variables, and identifying an anomaly based on the determination.

US Patent:

20220332324, Oct 20, 2022

Filed:

Apr 20, 2021

Appl. No.:

17/235607

Inventors:

- Plano TX, US
Ryan Mercer - Mountain View CA, US

International Classification:

B60W 40/09
B60W 50/08

Abstract:

The disclosure includes embodiments for identifying an origin of abnormal driving behavior for improved vehicle operation. A method includes identifying an abnormal driving behavior of a driver of a vehicle at a time T. The method includes identifying a set of events that occurred within a predetermined time Δt before time T. The method includes executing, by a processor, a cause-and-effect analysis on the set of events to determine one or more events from the set of events that caused the abnormal driving behavior. The method includes executing a strategy to reduce the abnormal driving behavior so that vehicle operation is improved.